Light and shadows in the iron chelation treatment of haematological diseases.
about
Oral deferiprone for iron chelation in people with thalassaemiaFerritin for the clinicianIron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseasesUse of deferiprone for iron chelation in patients with transfusion-dependent thalassaemia.Deferoxamine iron chelation increases delta-aminolevulinic acid induced protoporphyrin IX in xenograft glioma model.Influence of iron chelators on myocardial iron and cardiac function in transfusion-dependent thalassaemia: a systematic review and meta-analysis.Synthetic and natural iron chelators: therapeutic potential and clinical useClinical Impact and Cellular Mechanisms of Iron Overload-Associated Bone Loss.Beta-thalassemia.An update on disordered iron metabolism and iron overload.Chelation treatment in sickle-cell-anaemia: much ado about nothing?The new era of chelation treatments: effectiveness and safety of 10 different regimens for controlling iron overloading in thalassaemia major.Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platformSequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.Impact of psychosocial status and disease knowledge on deferoxamine adherence among thalassaemia major adolescents.Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide.A record of 1320 suspect, deferasirox-related, patient deaths reported in 2009: insufficient toxicity testing, low efficacy and lack of transparency may endanger the lives of iron loaded patients.First report of drug-induced esophagitis by deferasirox.
P2860
Q24200309-FEA247B9-1013-4C16-8C87-705F0AC2BFCBQ24642942-37F16DE0-5DA0-4572-B0EE-5A47D564BBF2Q28388335-28F84946-17A0-427F-91F2-54F90AA42463Q33397094-388A9C60-766E-48AA-9334-887B29CB02B3Q33872581-A41A59D8-321B-474E-928F-BFA81420537FQ37114840-A3B7285D-65A9-445A-95D0-41FB90ED81CFQ37290073-5B817D4D-DC5B-4A1C-9051-58742E599FF1Q37653861-E0F9DCAA-7B01-4E45-B205-E7ACF7CC059EQ37680651-AE84132A-F2D5-4E5C-803D-18E364266D3AQ37791615-B372B607-5961-4E32-9586-F623597035EEQ37894822-43A2AF75-515B-4FDC-BCEF-80544E164D8EQ39260564-CA896E4D-1318-495B-902B-E0AABD5CD4C6Q39529378-7376E679-FA7B-4D75-A270-279AB4EEBF85Q42601757-D7CB224F-1015-4694-8312-C6A0342A5C98Q43265086-55E721F7-01E6-44CA-A0C2-9101C261663BQ44522042-2F201FC8-6DCC-43C9-BAD1-7E894E62C4FDQ46209126-A370FA4A-96D9-476D-99EA-C9375EA15FB2Q48665941-E1785101-FF08-4361-85B8-2C3AF552C8DBQ50511953-53AD1208-B9F2-4014-91CE-C45F94B328F3
P2860
Light and shadows in the iron chelation treatment of haematological diseases.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Light and shadows in the iron chelation treatment of haematological diseases.
@en
type
label
Light and shadows in the iron chelation treatment of haematological diseases.
@en
prefLabel
Light and shadows in the iron chelation treatment of haematological diseases.
@en
P2860
P1476
Light and shadows in the iron chelation treatment of haematological diseases.
@en
P2093
Aurelio Maggio
P2860
P304
P356
10.1111/J.1365-2141.2007.06666.X
P407
P577
2007-08-01T00:00:00Z